NEW YORK, Oct. 29, 2014 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of Florida on behalf of investors who purchased IRadimed Corporation ("IRadimed" or the "Company") (Nasdaq:IRMD) securities between July 15, 2014 and September 2, 2014.
Click here to learn about the case: http://docs.wongesq.com/IRMD-Info-Request-Form-454. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period IRadimed failed to disclose that: (a) the Company's infusion pump systems had been significantly modified, a fact that could significantly affect the safety and/or effectiveness of the devices; (b) as a result of said modifications, the Company's products are "adulterated" and "misbranded" under applicable federal regulations; (c) the Company's mRidium 3860+ infusion pump requires separate FDA clearance from its mRidium 3860 and mRidium 3850.
On September 3, 2014, IRadimed announced it had received a warning letter from the FDA requesting the Company cease all activities that misbrand or adulterate its mRidium 3860, mRidium 3850, and mRidium 3860+ infusion pumps.
If you suffered a loss in IRadimed you have until November 10, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email email@example.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/IRMD-Info-Request-Form-454.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: firstname.lastname@example.orgSource:The Law Offices of Vincent Wong